Artículos
Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets.
Autores: Paoli A, Rubini A, Volek JS, Grimaldi KA.
Insulin analogues: modifications in the structure, molecular and metabolic consequences
Autores: de Luis DA, Romero E.
Potential of incretin-based therapies for non-alcoholic fatty liver disease.
Autores: Samson SL, Bajaj M.
Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.
Autores: Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ.
Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use).
Autores: Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J.
Experience over 12 years with home enteral nutrition in a healthcare area of Spain.
Autores: De Luis DA, Izaola O, Cuellar LA, Terroba MC, Cabezas G, De La Fuente B.
A randomized clinical trial with two doses of an enteral diabetes-specific suplements in elderly patients with diabetes mellitus type 2.
Autores: de Luis DA, Izaola O, de la Fuente B, Terroba MC, Cuellar L, Cabezas G.
BLOOD GLUCOSE AND INSULIN RESPONSES TO TWO HYPOCALORIC ENTERAL FORMULAS IN PATIENTS WITH DIABETES MELLITUS TYPE 2.
Autores: de Luis DA, Izaola O, de la Fuente B, Araújo K.
Genetic variation in the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and their influence on weight loss and insulin resistance under a high monounsaturated fat hypocaloric diet.
Autores: de Luis D, Aller R, Izaola O, Conde R, de la Fuente B, Sagrado MG.
Serum visfatin levels and metabolic syndrome criteria in obese female subjects.
Autores: de Luis DA, Aller R, Gonzalez Sagrado M, Conde R, Izaola O, de la Fuente B.